Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BWAY

HOLDFLAG

BrainsWay Ltd. · Healthcare · Israel · $641M · Avg Vol: $2M/d

51
StockRank
Get insider-trade alerts
Q
71
V
13
M
61
P/E (TTM)
71.9x
ROE
12.6%
D/E
0.1x
Dividend %
AI CONVICTION THESIS

BrainsWay has exceptional momentum M88 and quality Q70, but value at V14 is among the lowest in this run and far below the calibrated floor, and insiders sold, so stage one fails.

COMPANY DESCRIPTION

BrainsWay Ltd. develops and commercializes advanced non-invasive brain stimulation technology, Deep Transcranial Magnetic Stimulation (Deep TMS), for treating mental health disorders like depression and OCD. As a pioneer in Deep TMS technology, it holds FDA clearance for specific psychiatric conditions and benefits from a patented technology offering a unique treatment modality. BrainsWay is a specialized medical device company at the forefront of non-invasive neurological treatments, focused on expanding its proprietary Deep TMS platform's clinical applications.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue27.2M31.8M41.0M52.2M24.3%56.2M67.6M82.6M25.8%
EPS-0.21-0.40-0.130.090.20122.2%0.220.3470.4%
Shares33.1M33.2M37.6M39.2M+18.5%40.1M
Debt0.5M0.5M5.6M6.8M140.8%6.7M
Equity45.4M41.6M62.3M73.2M17.3%
Op CF-9.8M1.3M10.3M18.0M274.6%13.6M
Inv CF42.2M-37.4M30.3M-17.5M
Fin CF-1.5M-1.0M18.3M-2.2M
Loading 1Y...
PRICE (1Y)+7.0%
14.1014.7215.3315.9416.56Jun 26Jul 20Aug 7
SMA 50SMA 200

Close
$15.50
RSI (14)
42.2
52W High
$17.35
From 52W High
0.9%

SCORE BREAKDOWN

Quality
71
ROIC
10.9%76.7
ROE
12.6%78.6
GP/Assets
37.6%77.8
Op. Margin
12.9%71.5
FCF/Assets
2.7%58.4
Piotroski
783.8
Int. Cover
4.5x51.1
D/E Ratio
0.09x64.5
Current Ratio
3.34x57.8
Value
13
P/E (TTM)
71.9x13.7
EV/EBITDA
80.0x6.6
P/FCF
211.5x6.9
P/B
8.0x14.9
P/S
11.3x25.0
Div Yield
N/A
Momentum
61
52W High %
89%82.3
RS 6M
33%87.5
SMA 50/200
1.20x88.9
EPS Rev 4W
-48.2%0.7
EPS Rev 12W
-45.9%1.9
EPS Improve
+10%27.2
Q Growth
107%85.8

FUNDAMENTALS

Market Cap
$641M
P/E (Forward)
65.4x
Gross Margin
75.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BWAY are excluded.

TickerCompanyMkt CapStockRankSignal
BWAYBrainsWay Ltd.(you)$641M51HOLD
INMDInMode Ltd.$872M93STRONG BUY
1696.HKSisram Medical Ltd$134M90STRONG BUY
NNOXNano-X Imaging Ltd.$62M5STRONG SELL
SLGLSol-Gel Technologies Ltd.$268M34SELL
DRTSAlpha Tau Medical Ltd.$1.1B27SELL
KMDAKamada Ltd.$407M85STRONG BUY
BVC.LBATM Advanced Communications Ltd.$67M53HOLD
CGENCompugen Ltd.$216M86STRONG BUY
INCRInterCure Ltd.$55M37HOLD

Peer medians: ROE -2.9% · P/E 11.4x · Gross margin 19.6%

BrainsWay Ltd. (BWAY): Stock Score Summary

BrainsWay Ltd. (BWAY) has a MoatMap StockRank of 51/100 based on Quality (71/100), Value (13/100), and Momentum (61/100) factor scores. The current signal is HOLD. BrainsWay has exceptional momentum M88 and quality Q70, but value at V14 is among the lowest in this run and far below the calibrated floor, and insiders sold, so stage one fails.

BrainsWay Ltd. develops and commercializes advanced non-invasive brain stimulation technology, Deep Transcranial Magnetic Stimulation (Deep TMS), for treating mental health disorders like depression and OCD. As a pioneer in Deep TMS technology, it holds FDA clearance for specific psychiatric conditions and benefits from a patented technology offering a unique treatment modality. BrainsWay is a specialized medical device company at the forefront of non-invasive neurological treatments, focused on expanding its proprietary Deep TMS platform's clinical applications.

Key Financial Metrics

Price$15.50
Market Cap$641M
P/E (TTM)71.86
P/E (Forward)65.42
Price/Book7.96
Return on Equity12.6%
Return on Invested Capital10.9%
Debt/Equity0.09x
Gross Margin75.5%
Operating Margin12.9%
Revenue Growth34.6%
Free Cash Flow$3M

BrainsWay Ltd. operates in the Medical Devices industry, part of the Healthcare sector (Israel).

Frequently Asked Questions

What is BrainsWay Ltd.’s (BWAY) StockRank?
MoatMap’s StockRank for BrainsWay Ltd. (BWAY) is 51/100, with a Hold signal. It is a composite of Quality (71), Value (13), and Momentum (61) factor ranks across MoatMap’s 20,000+ stock universe.
Does BrainsWay Ltd. have an economic moat?
BrainsWay Ltd. (BWAY) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BrainsWay Ltd. a buy, hold, or sell?
MoatMap’s current signal for BrainsWay Ltd. (BWAY) is Hold, based on a StockRank of 51/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is BrainsWay Ltd. in?
BrainsWay Ltd. (BWAY) operates in the Healthcare sector, specifically the Medical Devices industry (Israel).